About Kartos Therapeutics
Kartos Therapeutics is a Healthcare company based in Redwood City (United States) founded in 2018, and was acquired by Ipsen in June 2026. Therapeutics for cancer treatment are developed by Kartos Therapeutics. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
Kartos Therapeutics was founded in 2018 and is based in Redwood City, United States. Focus is placed on the biotechnology sector, where therapeutics for cancer are developed. The lead candidate, Navtemadlin (KRT-232), an oral MDM2 inhibitor, targets Myelofibrosis, Polycythemia Vera, Acute Myeloid Leukemia, and Merkel Cell Carcinoma. Operations center on advancing these treatments through clinical development.
- Headquarters Redwood City, United States
- Stage Acquired
- SectorsHealthcare
- Website kartosthera.com
- Social LinkedIn
- Acquired by Ipsen (Jun 2026)
Investors in Kartos Therapeutics
Kartos Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ipsen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | 1929 | ipsen.com | Boulogne Billancourt, France |
Investor details for Kartos Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Kartos Therapeutics
2 dated milestones of Kartos Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Kartos Therapeutics is founded.
- Exit Acquired by Ipsen.
Competitors of Kartos Therapeutics
Kartos Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Kartos Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kartos Therapeutics
The website of Kartos Therapeutics (kartosthera.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 31.9% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Kartos Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kartos Therapeutics
Complete news archive for Kartos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kartos Therapeutics
Kartos Therapeutics was founded in 2018.
Kartos Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Kartos Therapeutics was founded in 2018 and is based in Redwood City, United States. Focus is placed on the biotechnology sector, where therapeutics for cancer are developed. The lead candidate, Navtemadlin (KRT-232), an oral MDM2 inhibitor, targets Myelofibrosis, Polycythemia Vera, Acute Myeloid Leukemia, and Merkel Cell Carcinoma. Operations center on advancing these treatments through clinical development.
Kartos Therapeutics's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
Kartos Therapeutics has 1 investor. Key investors include Ipsen.
Yes. Kartos Therapeutics was acquired by Ipsen in June 2026.